Last Modified: 3/4/2024
Location: FL, PR, USVI
Business: Part B
The Comprehensive Error Rate Testing (CERT) program has noted a high error rate for glucose monitor claims. The following information is provided to assist you in reducing these types of errors.
Medicare will consider coverage of a glucose monitor and related supplies when your patient's medical record shows they have diabetes and you have determined that your patient or a caregiver is sufficiently trained to use the prescribed device appropriately.
The Standard Written Order (SWO) for the glucose monitor and supplies must include the following:
• Patient name or Medicare Beneficiary Identifier (MBI)
• Order date
• General description of the item (may be a narrative description, a HCPCS code, HCPCS code narrative, or brand name/model number)
• For equipment - In addition to the description of the base item, the SWO may include all concurrently ordered options, accessories or additional features that are separately billed or require an upgraded code (List each separately).
• For supplies – In addition to the description of the base item, the durable medical equipment prosthetics, orthotics, and supplies (DMEPOS) order/prescription may include all concurrently ordered supplies that are separately billed (List each separately)
• Quantity to be dispensed, if applicable
• Treating practitioner name or NPI
• Treating practitioner's signature
Treatment regimen |
Basic coverage for test strips and lancets |
Prescribed testing frequency |
Insulin treated
|
|
|
Non-insulin treated
|
|
|
For your patients who require additional testing per day, or the quantities of supplies ordered exceed Medicare's standard utilization parameters, there are some additional documentation requirements that must be met. These are outlined in the LCD:
Basic requirements outlined above have been met; and,
Within the six months prior to ordering quantities of strips and lancets that exceed the utilization guidelines, you have had an in-person or Medicare approved telehealth visit with your patient to evaluate their diabetes control and their need for the specific quantity of supplies that exceeds the usual utilization amounts described above; and,
A non-adjunctive CGM can be used to make treatment decisions without the need for a stand-alone blood glucose monitor (BGM) to confirm testing results. An adjunctive CGM requires the user verify their glucose levels or trends displayed on a CGM with a BGM prior to making treatment decisions. On February 28, 2022, CMS determined that both therapeutic/non-adjunctive and non-therapeutic/adjunctive CGMs may be classified as DME.
CGMs and related supplies are covered by Medicare when all of the following coverage criteria (1-5) are met:
1. Your patient has diabetes mellitus; and
2. You have concluded that your patient or their caregiver that sufficient training using the CGM prescribed as evidenced by providing a prescription; and
3. The CGM is prescribed in accordance with its FDA indications for use: and,
4. The patient for whom a CGM is being prescribed, to improve glycemic control meets at least one of the following:
• The patient is insulin treated, or
• The patient has a history of problematic hypoglycemia with documentation of least one of the following:
• Recurrent (more than one) level 2 hypoglycemic events (glucose<54mg/dL (3.0mmol/L)) that persists despite multiple (more than one) attempts to adjust medications (s) and/or modify the diabetes treatment plan; or
• A history of one level 3 hypoglycemic event (glucose<54mg/dL (3.0mmol/L)) characterized by altered mental and/or physical state requiring 3rd party assistance for treatment of hypoglycemia.
5. Within six months prior to ordering the CGM, you have an in-person visit or Medicare approved telehealth visit with your patient to assess adherence to their CGM regimen and diabetes treatment plan.
Publication history:
August 25, 2023, Added reference “Step-By-Step Guide to Ordering Diabetic Testing Supplies for Medicare Patients using Home Glucose Monitors”, removed language in regard to therapeutic/non- therapeutic CGM, revised coverage criteria 1-5 for CGMs; added information for CGMs continued coverage: added information in regard to the end of the COVID-19 PHE telehealth visits.
July 18, 2022, Added references to Glucose Monitors LCD L33822, External Infusion Pumps l33794 and LCD-related policy article A52507; revised the diabetic testing regiment language; added information in regard to treatment with therapeutic /non-adjunctive CGM and non-therapeutic/adjunctive CGM; changed insulin injections to insulin administrations; removed the four or more times a day testing requirement; added information in regard to non-enforcement directives and waivers associated with the COVID-19 PHE.
July 2020, Revised
November 9, 2019, Originally published.
First Coast Service Options (First Coast) strives to ensure that the information available on our provider website is accurate, detailed, and current. Therefore, this is a dynamic site and its content changes daily. It is best to access the site to ensure you have the most current information rather than printing articles or forms that may become obsolete without notice.